[pt] O comportamento eletroquímico e o desenvolvimento de metodologias eletroanalíticas para a determinação de zidovudina (AZT), lamivudina (3TC) e zalcitabina (DDC) em medicamentos foram investigados no presente trabalhoatravés de técnicas voltamétricas. Estas substâncias possuem atividade antiretroviral, sendo utilizadas no tratamento de indivíduos portadores de HIV. AZT, 3TC e DDC sofrem redução na superfície do eletrodo de mercúrio. Ainfluência dos parâmetros eletroquímicos, tais como, velocidade de varredura, amplitude, natureza do eletrólito suporte e pH foram estudados para selecionar as melhores condições para quantificar estes princípios ativos em formulações farmacêuticas. A redução da zidovudina ocorre em apenas uma etapa, sendo esta atribuída à redução do grupo azida (-N3), originando em um pico de potencial de-970 mV vs Ag/AgCl (3 mol L-1), utilizando tampão fosfato, pH 8,0. A faixa linear encontrada foi de 0,25 a 1,25 mg L-1. O mecanismo de redução da zidovudina envolve a participação de 4 elétrons e 2 prótons. Adicionalmente novos estudos eletroquímicos foram desenvolvidos para a determinação de lamivudina e de zalcitabina através da voltametria em pulso diferencial em tampão Clark-Lubs, pH 2,0, onde se obteve um pico no potencial de -1160 e -1180 mV, respectivamente. Lamivudina obteve faixa linear de 2,28 a 8,85 mg L-1 e zalcitabina de 10,0 a 23,3 mg L-1. O mecanismo de redução destas drogas envolve a participação de números iguais de prótons e elétrons. Todas as metodologias desenvolvidas também foram validadas. / [en] The electrochemical behaviour and the development of an analytical methodology for the zidovudine (AZT), lamivudine (3TC) and zalcitabine (DDC)determination in drugs using voltammetrics techniques were the objectives of the current study. These drugs have been extensively used in the treatment of HIV patients because its antiretroviral activity. The AZT, 3TC and DDC are reduced at a hanging mercury drop electrode (HMDE). The influence of electroanalytical parameters such as, scan rate, amplitude, nature of the support electrolyte and pH in the signal was verified to select the best conditions for quantifying these drugs in pharmaceutical forms. The obtained results had showed AZT, in solution of pH 8.0 of phosphate buffer, with only one reduction in -970 mV vs Ag/AgCl (3 mol L-1). This peak is due to reduction of the azido group present on zidovudine molecule. The linear range of standards is from 0.25 to 1.25 mg L-1. The electrodic mechanism involving the participation of 4 electrons and 2 protons in the reduction of AZT molecules. News studies were development for lamivudine and zalcitabine determination by differential pulse voltammetry in solution of pH 2.0 of Clark-Lubs buffer, with only one reduction in - 1160 and -1180 mV, respectively. Lamivudine has been the linear range of standards from 2.28 to 8.85 mg L-1 and zalcitabine from 10.0 to 23.3 mg L-1. The mechanism of these drugs involving the participation of the same number of electrons and protons. All these analytical methods were validated.

A novel mucoadhesive poly[acrylic acid-co-poly(ethylene glycol) monomethylether monomethacrylate-co-2-(N, N-Dimethylamino)ethyl methacrylate], [poly(AA-PEGMM-DMEMA)], was designed and synthesized based on a hypothesis that interactions between the negative charged surface of the buccal mucosa and the positive charged constituent in bioadhesive would increase the mucoadhesion. Introducing the cationic monomer DMEMA to poly(AA-PEGMM) increased the Lewis acid-base interaction between the polymer and the buccal mucosa, which led to a thermodynamic favorable mucoadhesion process. The polymer containing 1% DMEMA yielded the highest force of mucoadhesion among the polymers studied. The ATR-FTIR study revealed that intrapolymer interactions between the carboxyl groups in AA and the amino groups in DMEMA and interactions between polymer and buccal surface played important roles in the mucoadhesion of poly(AA-PEGMM-DMEMA). The optimal mucoadhesion can be achieved by balancing these two interactions. The thermodynamic analysis revealed the contributions of Lifshitz-van der Waals interaction and Lewis acid-base interaction, such as the interactions between the hydroxyl groups and the ester groups, to the mucoadhesion. A general trend of mucoadhesion of the polymer can be predicted from the total free energy of adhesion (Δ G TOT ) at different hydration levels. A mathematical model was established to quantitatively describe the contributions of the three stages that involved in the process of adhesion to the force of mucoadhesion by the surface free energy, the total free energy of adhesion, and the hydration of the polymer. Zalcitabine (ddC) was selected as the model drug in the drug loading, in vitro release and permeation studies. Changing the pH of the swelling medium can greatly affect the swelling of the polymer. The drug loading increased 3.6 times when the pH of the loading solution was changed from 2.2 to 8. The process of the swelling and drug release followed Fickian diffusion mechanism. Compared to the permeation of ddC through the polymer, the permeation of ddC through the buccal mucosa was the rate-limiting barrier to the transbuccal delivery of ddC. ddC permeated through buccal mucosa by passive diffusion over the range of concentrations examined. The total permeability of ddC through the buccal mucosa was contributed by the permeation of ionized and unionized species of ddC. A bilayer diffusion model was established to describe the relations among the permeability of the epithelium, the connective tissue and the full-thickness buccal mucosa. The histological study revealed that the basal lamina within the epithelium of buccal mucosa acted as the major barrier to the permeation of ddC. The permeation of ddC through the buccal mucosa can be effectively enhanced by co-administrating a penetration enhancer sodium glycodeoxycholate (GDC). GDC enhanced the buccal permeability of ddC up to 32 times. A zero-order delivery of the currently approved dosage of ddC can be achieved by a poly(AA-PEGMM-DMEMA) transbuccal drug delivery device with GDC as the penetration enhancer. The transbuccal delivery is a potential route for the administration of ddC.